We have demonstrated that the S 1 and S 2 subsites of human tissue kallikrein (hK1) play determinant roles in the recognition and hydrolysis of substrates. The presence of serine at position P 1 and arginine at P 2 resulted in the best substrate, Abz-Ala-Ile-Lys-Phe-Phe-Ser-Arg-Gln-EDDnp, which was derived from the kallistatin reactive-centre loop sequence and quencher groups o-aminobenzoic acid (Abz) and N- (2,4-dinitrophenyl)ethylenediamine (EDDnp). Serine and arginine are also the residues at positions P 1 and P 2 in human kininogen, from which hK1 releases Lys-bradykinin. Several peptide analogues of Abz-Ala-Ile-Lys-Phe-Phe-Ser-ArgGln-EDDnp, in which the Ser and Arg residues were substituted with various other amino acids, were synthesized and tested as substrates. Most of them were hydrolysed slowly, although they showed significant binding to hK1, as demonstrated by their competitive inhibition constants (K i ). Using this information, six peptides were designed, synthesized and assayed as inhibitors of hK1. Abz-Lys-Phe-Phe-Pro-Arg-Gln-EDDnp, Abz-Lys-Phe-ArgPro-Arg-Gln-EDDnp and acetyl-Lys-Phe-Phe-Pro-Leu-Glu-NH 2 inhibited hK1 in the range 20-30 nM (letters in italics denote the D-form of the amino acid). The peptide acetyl-Lys-Phe-Phe-ProLeu-Glu-NH 2 was a weak inhibitor for other serine proteases, as indicated by the higher K i values compared with hK1, but this peptide was a potent inhibitor of human plasma kallikrein, which has a K i value of 8 nM. This result was surprising, since this enzyme is known to be a restricted arginyl-hydrolase. In conclusion, acetyl-Lys-Phe-Phe-Pro-Leu-Glu-NH 2 can be used as a leader compound to design specific inhibitors for hK1, plasma kallikrein, or for both at same time, if the inhibition of kinin release is the main goal.
INTRODUCTION
Human tissue kallikrein (hK1) (EC 3.4.21.35) is a member of a family of three closely related serine proteases [1, 2] , which includes two enzymes expressed in prostate, namely prostatespecific antigen (PSA; also called hK3) and a trypsin-like enzyme, hK2. This classical view has been altered by the inclusion of 14 genes in the human kallikrein gene family, some of which have been correlated with carcinogenesis [3] . hK1 is the only tissue kallikrein with established functions, which include release of Lys-bradykinin (kallidin) in inflammatory processes, such as arthritis, asthma and rhinitis [4] [5] [6] , and the processing of hormone and other peptide precursors [1, 2] . hK1, and the cognate enzymes in mammals, release the vasoactive decapeptide Lys-bradykinin (Lys-BK) by cleavage at Met 379 -Lys 380 and Arg 389 -Ser 390 in limited proteolysis from high-and low-molecular-mass kininogens [7] . The only exceptions known so far are rat tissue kallikrein (rK1), which cleaves a Lys-Arg bond and releases bradykinin from bovine and rat kininogens [8, 9] , and mouse submandibular tissue kallikrein [10] , which also releases bradykinin. The efficiency of cleavage at the Met-Lys bond by hK1 is dependent on the extension of the substrates, as demonstrated by internally quenched fluorescent peptides with the sequence of human kininogen [11, 12] . hK1 can also hydrolyse substrates that contain a pair of phenylalanines, for example in the reactive-site loop of hK1-binding protein, a specific serpin for tissue kallikrein called Abbreviations used: hK1, human tissue kallikrein; Abz, o-aminobenzoic acid; EDDnp, N-(2,4-dinitrophenyl)ethylenediamine; MALDI-TOF MS, matrixassisted laser-desorption ionization-time-of-flight MS; PTI, pancreatic trypsin inhibitor; TFA, trifluoroacetic acid; λ em , emission wavelength; λ ex , excitation wavelength. 1 To whom correspondence should be addressed (e-mail juliano.biof@epm.br).
kallistatin [13, 14] , as well as in somatostatin [15] . Although hK1 possesses homology with trypsin, the crystal structures of human and porcine tissue kallikrein [16, 17] show that their S 1 (see Schechter and Berger nomenclature [18] ) sites are enlarged, mainly owing to the insertion of an additional residue, Pro 219 , which is in the cis configuration. This unique feature of tissue kallikrein allows its S 1 subsite to accept Arg, as well as a larger and hydrophobic side chain, such as that of Phe.
In the present paper, we examined the S 1 and S 2 subsite specificity of hK1, using the internally quenched fluorescent peptide Abz-Ala-Ile-Lys-Phe-Phe-Ser-Arg-Gln-EDDnp as a reference [where Abz is o-aminobenzoic acid and EDDnp is N-(2,4-dinitrophenyl)ethylenediamine]; this peptide is a segment of the reactive-centre loop sequence of kallistatin that has been used previously for evaluation of hK1 specificity at non-prime subsites [19] . Abz and EDDnp are the fluorescent donor and acceptor groups respectively, and glutamine was introduced as a necessary result of the solid-phase peptide synthesis strategy employed [20] .
MATERIAL AND METHODS

Reagents
Homogeneous preparations of hK1, obtained as described previously [21] , were kindly provided by Dr J. Chao of the Medical University of South Carolina, Charleston, SC, U.S.A.
The molar concentrations of enzyme solutions were determined by active-site titration with 4-nitrophenyl-4-guanidinobenzoate [22] .
Peptide synthesis
All the intramolecularly quenched fluorogenic peptides were obtained by a solid-phase peptide synthesis strategy, the details of which are provided elsewhere [20] . An automated bench-top simultaneous multiple solid-phase peptide synthesizer (PSSM 8 system, Shimadzu, Tokyo, Japan) was used for the solid-phase synthesis of all the peptides by the fluoren-9-ylmethoxycarbonyl (Fmoc) procedure. The final deprotected peptides were purified by semi-preparative HPLC using an Econosil C-18 column (10 µm, 22.5 mm × 250 mm) and a two-solvent system: buffer A, trifluoroacetic acid (TFA)/H 2 O (1:1000, v/v) and buffer B, TFA/acetonitrile/H 2 O (1:900:100, by vol.). The column was eluted at a flow rate of 5 ml/min with a 10-50 % (or 30-60 %) gradient of solvent B over 30 or 45 min. Analytical HPLC was performed using a binary HPLC system (Shimadzu) with a SPD-10AV Shimadzu UV-Vis detector and a Shimadzu RF-535 fluorescence detector, coupled to an Ultrasphere C-18 column (5 µm, 4.6 mm × 150 mm) which was eluted with solvent systems A and B at a flow rate of 1 ml/min and a 10-80 % gradient of B over 20 min. The HPLC column eluates were monitored by their absorbance at 220 nm and by fluorescence emission at 420 nm following excitation at 320 nm. The molecular mass and purity of synthesized peptides were checked by matrix-assisted laser-desorption ionization-time-of-flight (MALDI-TOF) MS (TofSpec-E; Micromass, Manchester, U.K.) and/or peptide sequencing using a protein sequencer PPSQ-23 (Shimadzu).
Kinetic assays
Hydrolysis of the fluorogenic peptidyl substrates was performed in 20 mM Tris/HCl and 1 mM EDTA, pH 9, at 37
• C and followed by measuring the fluorescence at an emission wavelength (λ em ) of 420 nm and an excitation wavelength (λ ex ) of 320 nm in a Hitachi F-2000 spectrofluorimeter. The 1 cm path length cuvette, containing 2 ml of the substrate solution, was placed in a thermostatically controlled cell compartment for 5 min before the enzyme solution was added and the increase in fluorescence with time was continuously recorded for 10 min. The slope was converted into mol of hydrolysed substrate/min, based on the fluorescence curves of standard peptide solutions before and after total enzymic hydrolysis. The concentration of the peptide solutions was determined by colourimetric determination of the 2,4-dinitrophenyl group (17300 M −1 · cm −1 molar absorption at 365 nm). The enzyme concentration for initial rate determination was chosen at a level intended to hydrolyse less than 5 % of the substrate present. The kinetic parameters were calculated according to Wilkinson [23] , as well as by using Eadie-Hofstee plots. All the obtained data were fitted to nonlinear least square equations using Grafit v 3.0 from Erithacus Software.
Inhibition assay
The hydrolysis of the fluorogenic peptide substrate Pro-Phe-Phe-7-methyl coumarine amide (K m = 70 µM, k cat = 12.5 s −1 [15] ; where italics denote the D-form of the amino acid) was followed by measuring the fluorescence at λ em = 480 nm and λ ex = 360 nm in a Hitachi F-2000 spectrofluorimeter, at 37
• C in 20 mM Tris/HCl, pH 9.0, containing 1 mM EDTA buffer. A 1 cm path length cuvette containing 2 ml of 30 µM substrate solution was placed in the thermostatted cell compartment for 5 min before the enzyme solution was added to 0.5 nM final concentration, and the increase in fluorescence with time (velocity) was continuously recorded for up to 5 min. Small aliquots of a highly concentrated inhibitor solution were added with minimal solution, and the decreased velocity was read for up to 5 min to ensure that no more than 5 % of the initial substrate concentration was hydrolysed by the end of the assay. The K i values for competitive inhibition assays of the peptides were determined according to Nicklin and Barrett [24] .
Determination of cleaved bonds
The cleaved bonds were identified by isolation of the fragments by HPLC and the retention times of the fluorescent Abz-containing fragments were compared with authentic synthetic sequences and/or by molecular mass, which was determined by MALDI-TOF MS (TofSpec-E; Micromass).
RESULTS
P 1 position
The kinetic parameters for hydrolysis of the peptides derived from the internally quenched fluorescent peptide Abz-Ala-IleLys-Phe-Phe-Ser-Arg-Gln-EDDnp with modifications at the P 1 position are presented in Table 1 . We have previously reported good substrates for hK1 with synthesized peptides derived from this reference peptide [19] , but with modifications at positions P 4 -P 1 . Most of the peptides from the family presented here, modified at the P 1 position, were poorly hydrolysed. In fact, only substrates having Gln, Ser, Thr and Ile (peptides VI, VIII, IX and X respectively) were hydrolysed to an extent that allowed Table 1 Kinetic parameters and inhibiton constant (K i ) for the simple linear competitive inhibition of hK1 for the internally quenched fluorescent peptides derived from the reactive centre loop of kallistatin, with modifications at the P 1 position Conditions: 20 mM Tris-HCl and 1 mM EDTA, pH 9, at 37 • C. *Poorly hydrolysed means that at least 70 % of the initial peptide concentration (10 µM) remained intact after a 4-h incubation period with 1 nM hK1 (the usual kinetic assay enzyme concentration). The cleavage point was determined after an overnight incubation. †A resistant peptide was one that, for the former conditions, presented a hydrolysis rate less than 10 %. ‡K i determined in 20 mM Tris/HCl and 1 mM EDTA, pH 9, at 37 • C over the hydrolysis of 20 µM Pro-Phe-Phe-methyl coumarine amide (K m = 70 µM, k cat = 12.5 s −1 [15] ), employing 1 nM hK1. Cleavage sites are indicated with an arrow (↓).One-letter symbols have been used to represent amino acids and letters in bold denote the mutated residue. the determination of the kinetic parameters. All the other peptides were recognized by hK 1 and were able to effectively bind to the active site of the enzyme, as indicated by the low K i values, and limited hydrolysis was observed only after 4 h of incubation with hK1. The K i values for the modifications at P 1 were approx. 0.30 µM. A proline residue at this position resulted in a peptide (V), which was completely resistant to hydrolysis but was able to inhibit hK 1 with the lowest K i value throughout the series. It is noteworthy that peptide VIII (containing a serine residue) was hydrolysed with a specificity constant (k cat /K m ) that was 50-fold higher than other susceptible peptides containing Gln, Thr and Ile (peptides VI, IX and X respectively), and this difference was due mainly to the higher catalytic constant (k cat ) of peptide VIII hydrolysis.
P 2 position
The kinetic parameters for hydrolysis of the peptides derived from the internally quenched fluorescent peptide Abz-Ala-Ile-Lys-PhePhe-Ser-Arg-Gln-EDDnp, with modifications at the P 2 position, are presented in Table 2 . Although all the peptides of this family contain Ser at P 1 , which was the best amino acid residue at this position, only the peptides with Arg, Ala, Pro, Ser and Lys (VIII, XIII, XVII, XIX and XXII respectively in Table 2 ) were hydrolysed with velocities that allowed the determination of the kinetic parameters. The S 2 subsite of hK1 also seems to have a specificity as restricted as that of its S 1 subsite for the hydrolysis of peptide substrates. The most efficiently hydrolysed peptide was the reference peptide (peptide VIII in Table 2 ), which contains Arg at the P 2 position. All the poor substrates of this series were assayed as competitive inhibitors, and the K i values obtained were in the range 0.2-1.7 µM. The lowest K i value was obtained with the peptide XV that contained Leu in the P 2 position. Table 3 presents the K i values for the peptides synthesized, based upon the information gathered from Tables 1 and 2 , and from previously reported specificity studies at non-prime sites of hK1 subsites [19] . In the peptides Abz-Lys-Phe-Phe-Pro-Arg-GlnEDDnp and Abz-Lys-Phe-Arg-Pro-Arg-Gln-EDDnp (XXIV and XXV in Table 3 ; letters in italics denote the D-form of the amino acid), Lys and Arg were introduced in their D-enantiomeric form in order to provide resistance to hydrolysis and solubility to the peptides. In addition, the K m values for the peptides containing Lys at P 3 positon [19] and Arg at P 2 (Table 2) were in the lower range of the obtained values. The amino acid Phe was maintained in the P 2 position because it is present in the best synthetic short substrates [25, 26] . Phe or Arg were introduced at the P 1 position of these inhibitors in order to compare the fitting of these amino acids at the S 1 subsite of hK1. Pro was maintained in all peptides because its presence at P 1 resulted in resistance of peptide V and a low K i value (Table 1 ). Abz was substituted by an acetyl group (peptides XXVI to XXIX), and the effects of Gln and EDDnp were examined in peptides XXVII and XXVIII, in which they were removed. Arg and Phe at P 1 in this setting of peptides have the same effect in binding to the enzyme. The substitution of Abz with an acetyl group increased the K i value one order of magnitude (compare peptides XXV and XXVI). The C-terminal Gln-EDDnp seemed to play a significant role in the binding of these peptides, because the highest K i value was obtained with the peptide XXVII, in which Gln-EDDnp is absent. When only EDDnp was removed (compare peptides XXVI and XXVIII), no significant variation was observed in the K i values. Finally, the peptide XXIX was synthesized by replacing Leu and Glu-amide with D-Arg and EDDnp respectively, and resulted in a inhibitor of hK1 with K i of 0.029 µM, which is similar to values obtained for the peptides XXIV and XXV (Table 3) . Leu was introduced in peptide XXIX because with this amino acid at P 2 , the lowest K i value was obtained in the series shown in Table 2 , and Glu was introduced to substitute the negative environment provided by the two NO 2 groups of EDDnp.
Design of inhibitors
The inhibitory specificity activity of acetyl-Lys-Phe-Phe-ProLeu-Glu-NH 2 for hK1 was evaluated by comparing the inhibitory effect of this peptide on human thrombin, activated factor X (FXa), plasmin, trypsin, cathepsin G and plasma kallikrein. Surprisingly, as shown in Table 4 , human plasma kallikrein was inhibited by acetyl-Lys-Phe-Phe-Pro-Leu-Glu-NH 2 with a K i value which was lower than that of hK1. All other proteases were less susceptible to inhibition by this peptide. 
DISCUSSION
The specificities of the subsites S 1 and S 2 of hK1 play determinant roles in the recognition and hydrolysis of substrates. The presence of Ser and Arg at positions P 1 and at P 2 respectively, resulted in the best substrate (Abz-Ala-Ile-Lys-Phe-Phe-Ser-Arg-GlnEDDnp) out of those derived from the kallistatin reactive-centre loop sequence. Any other amino acid at P 1 or P 2 resulted in peptides that were hydrolysed very slowly, and the k cat constants, for those with values that could be determined, were at least one order of magnitude lower than that of the hydrolysis of Abz-Ala-Ile-Lys-Phe-Phe-Ser-Arg-Gln-EDDnp. It is noteworthy that Lys-bradykinin (kallidin) is released by hK1 from human kininogen, which is its natural substrate, by two cleavage events, one faster with Ser at P 1 position for hydrolysis of Arg 389 -Ser 390 bond, and a second with Arg at P 2 for the hydrolysis of Met 379 -Lys 380 bond [11] . According to these observations, two very efficient substrates for hK1 were described previously, AbzPhe-Arg-Ser-Arg-EDDnp (k cat = 5.7 s
, and the short internally quenched fluorescent peptide Abz-Phe-Arg-Ser-EDDnp (k cat = 1.3 s [28] . In addition, somatostatin was described as being hydrolysed at the Phe-Trp bond by hK1 with Lys present at the P 2 position; however, an efficient substrate derived from somatostatin was obtained by putting Ser and Arg at P 1 and P 2 positions respectively, resulting in the internally quenched fluorescent peptide Abz-Lys-Asn-PhePhe-Ser-Arg-Gln-EDDnp (k cat = 2.5 s [19] . Therefore the specificities of S 1 and S 2 of tissue kallikrein seems to be as determinant as that of S 2 , which requires hydrophobic, and preferentially aromatic, amino acids [19, 25] because of the hydrophobic crevice between Tyr 99 and Trp 215 at the S 2 subsite of human and porcine tissue kallikrein [16, 17] . The S 1 and S 2 subsites of tissue kallikreins are not well defined, although Ala and Lys in bovine pancreatic trypsin inhibitor (PTI) occupy these subsites of porcine tissue kallikrein in the crystal structure of the complex formed by them [17] . All together, these structural and kinetic observations suggest that S 1 preferentially accepts residues with short side chains and S 2 preferentially accepts residues with basic side chains. In the described structure of PTI-tissue kallikrein complex, S 1 contains a histidine residue that could establish convenient hydrogen bonds with the serine side chain, and the basic residue of PTI interacts with the main chain of the enzyme and is partially exposed to solvent. In addition, the results presented in Tables 1  and 2 suggest that the occupancy of S 1 and S 2 hK1 subsites determines whether a particular peptide will be preferentially a substrate or an inhibitor. As some hydrolysis was detected with most of the assayed peptides, an acyl-enzyme intermediate must be formed with each peptide, but the amino leaving fragment of those slowly hydrolysed peptides could stay in the hK1 for a longer time, allowing a back reaction. This situation would be similar to those observed for classical serine proteinase inhibitors, where the favourable conditions of the back reaction seems to be the main component for the high inhibitory activity of the classical proteinaceous inhibitors [29] . In these inhibitors, the retention of the amino fragment of the inhibitor is guaranteed by the rigidity of the inhibitor-enzyme structure provided by a network of hydrogen bonds inside the inhibitor. In the case of our small peptides, the retention of the amino fragment could be a result of its strong interaction with the prime subsites of hK1.
Using the information obtained with the peptides presented in Tables 1 and 2 , six peptides were designed as inhibitors of hK1 (Table 3 ). Three out of the six peptides (Abz-LysPhe-Phe-Pro-Arg-Gln-EDDnp, Abz-Lys-Phe-Arg-Pro-Arg-GlnEDDnp and acetyl-Lys-Phe-Phe-Pro-Leu-Glu-NH 2 ) inhibited hK1 in the range 20-30 nM. They were resistant to hydrolysis by hK1 and, surprisingly, hK1 accepted Pro at S 1 and D-amino acids at S 3 and S 2 subsites. It is noteworthy that the inhibitory activity of the peptide acetyl-Lys-Phe-Phe-Pro-Leu-Glu-NH 2 was due mainly to the presence of Glu at the S 3 position. This result suggests that the negative side chain of Glu could be playing the same role of the EDDnp, in which NO 2 groups introduce a strong polarization on this group and expose a negative group that could interact favourably with hK1. The peptide acetyl-Lys-Phe-Phe-Pro-Leu-Glu-NH 2 inhibited other serine proteases with higher K i values, apart from human plasma kallikrein which has a K i value of 8 nM. This is a surprising result, since this enzyme is known to be a restricted arginylhydrolase, and a specific inhibitor of human plasma kallkrein [30] , PKSI-527 (trans-4-aminomethylcyclohexenecarbonyl-Lphenylalanine-4-carboxymethylanilide), was described, which is supposed to interact with the negatively charged S 1 subsite of human plasma kallikrein with the trans-4-aminomethylcyclohexenecarbonyl moiety of the molecule. Although acetylLys-Phe-Phe-Pro-Leu-Glu-NH 2 has the basic side chain of D-lysine, it is not reasonable to propose that the lysine side chain interacts with the S 1 subsite of plasma kallikrein.
In conclusion, we report a restricted specificity of subsites S 1 and S 2 of hK1 and we also found a particular peptide sequence that could be a leader compound to design specific inhibitor for hK1 or for plasma kallikrein or for both at same time. The development of compounds that inhibit both kallikreins could be of even more interest if the inhibition of kinin release is the main goal.
